FOR IMMEDIATE RELEASE
Contact: Eric N. Valor
(firstname.lastname@example.org – 831-708-8799)
SciOpen Research Group Launches
Crowd Source Financing for Exploration of Novel Treatment for ALS
March 3, 2014 – SciOpen Research Group, Inc. (SRG), the
world’s first fully-functional “guerrilla biotech”, announced its
currently ongoing preclinical testing program of a novel molecule in the battle against Amyotrophic Lateral Sclerosis (ALS). ALS, also known as “Lou Gehrig’s Disease”, is a fatal neurodegenerative disease in which the nerves supplying commands to the muscles die, leaving the patient paralyzed and eventually succumbing to death from respiratory failure. Average survival time from diagnosis is 2-5 years. ALS has an incidence roughly similar to that of Multiple Sclerosis (MS) but currently has no effective treatment.
SRG is testing a new molecule called J147, developed by Dr. David Schubert at The Salk Institute for Biomedical Studies. J147, a
synthetic derivative of curcumin, demonstrated profound efficacy in the mouse model of Alzheimer’s, even reversing memory deficits in aged mice of that model. Although it was originally developed for Alzheimer’s, SRG Founder Eric Valor recognized the similarity in J147-affected pathways to those of ALS. SRG arranged to have Dr. Schubert test J147 in the mouse model of ALS. That work commenced in the last week of January, 2014.
SRG, a public charity under IRS regulation 501c3, is launching a crowdfunding campaign to fund microscopic tissue examination of the mice used in the J147 project. This tissue examination will determine motor neuron survival between treated and untreated specimens, along with other histological data. The data gathered from this phase of the project will be crucial to understanding the effect of J147 in tissue relevant to ALS. As per its mission and status as a public charity, SRG will publish the findings in an Open-Access journal freely available to the public. The crowdfunding campaign will be hosted on the site Indiegogo.
About SciOpen Research Group:
SRG is a team of Persons(s) with ALS (PALS), citizen scientists, doctors, and pharmaceutical industry professionals who are frustrated by the limitations of the current drug development process aimed at treating ALS. SRG seeks out interesting new molecules or repurposed drugs to test in various models of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).
SRG is a new type of biotech called a “guerrilla biotech”. It is young, small, aggressive, and is the new wave of how science will be done in the future. By outsourcing and utilizing Cloud-based infrastructure, it can do the same science as large institutions for a fraction of the cost.
About the Salk Institute for Biological Studies:
The Salk Institute for Biological Studies is one of the world’s preeminent basic research institutions, where internationally renowned faculty probe fundamental life science questions in a unique, collaborative, and creative environment. Focused both on discovery and on mentoring future generations of researchers, Salk scientists make groundbreaking contributions to our understanding of cancer, aging, Alzheimer’s, diabetes, and infectious diseases by studying neuroscience, genetics, cell and plant biology, and related disciplines.
Faculty achievements have been recognized with numerous honors, including Nobel Prizes and memberships in the National Academy of Sciences. Founded in 1960 by polio vaccine pioneer Jonas Salk, M.D., the Institute is an independent nonprofit organization and architectural landmark.